TSE:4528Pharmaceuticals
Ono Pharmaceutical (TSE:4528) Valuation in Focus After Positive Phase 2 Trial Updates for Pipeline Drugs
Ono Pharmaceutical (TSE:4528) drew investor attention after announcing new Phase 2 results for two experimental treatments. Early findings for ONO-2808 showed slower disease progression in multiple system atrophy. ONO-4578 met a key trial goal in advanced gastric cancer.
See our latest analysis for Ono Pharmaceutical.
Shares of Ono Pharmaceutical have been showing some momentum lately, with a 12% share price return over the past 90 days and 7.5% year-to-date. This signals renewed optimism...